Literature DB >> 23993280

Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.

Harvey A Whiteford1, Louisa Degenhardt, Jürgen Rehm, Amanda J Baxter, Alize J Ferrari, Holly E Erskine, Fiona J Charlson, Rosana E Norman, Abraham D Flaxman, Nicole Johns, Roy Burstein, Christopher J L Murray, Theo Vos.   

Abstract

BACKGROUND: We used data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) to estimate the burden of disease attributable to mental and substance use disorders in terms of disability-adjusted life years (DALYs), years of life lost to premature mortality (YLLs), and years lived with disability (YLDs).
METHODS: For each of the 20 mental and substance use disorders included in GBD 2010, we systematically reviewed epidemiological data and used a Bayesian meta-regression tool, DisMod-MR, to model prevalence by age, sex, country, region, and year. We obtained disability weights from representative community surveys and an internet-based survey to calculate YLDs. We calculated premature mortality as YLLs from cause of death estimates for 1980-2010 for 20 age groups, both sexes, and 187 countries. We derived DALYs from the sum of YLDs and YLLs. We adjusted burden estimates for comorbidity and present them with 95% uncertainty intervals.
FINDINGS: In 2010, mental and substance use disorders accounted for 183·9 million DALYs (95% UI 153·5 million-216·7 million), or 7·4% (6·2-8·6) of all DALYs worldwide. Such disorders accounted for 8·6 million YLLs (6·5 million-12·1 million; 0·5% [0·4-0·7] of all YLLs) and 175·3 million YLDs (144·5 million-207·8 million; 22·9% [18·6-27·2] of all YLDs). Mental and substance use disorders were the leading cause of YLDs worldwide. Depressive disorders accounted for 40·5% (31·7-49·2) of DALYs caused by mental and substance use disorders, with anxiety disorders accounting for 14·6% (11·2-18·4), illicit drug use disorders for 10·9% (8·9-13·2), alcohol use disorders for 9·6% (7·7-11·8), schizophrenia for 7·4% (5·0-9·8), bipolar disorder for 7·0% (4·4-10·3), pervasive developmental disorders for 4·2% (3·2-5·3), childhood behavioural disorders for 3·4% (2·2-4·7), and eating disorders for 1·2% (0·9-1·5). DALYs varied by age and sex, with the highest proportion of total DALYs occurring in people aged 10-29 years. The burden of mental and substance use disorders increased by 37·6% between 1990 and 2010, which for most disorders was driven by population growth and ageing.
INTERPRETATION: Despite the apparently small contribution of YLLs--with deaths in people with mental disorders coded to the physical cause of death and suicide coded to the category of injuries under self-harm--our findings show the striking and growing challenge that these disorders pose for health systems in developed and developing regions. In view of the magnitude of their contribution, improvement in population health is only possible if countries make the prevention and treatment of mental and substance use disorders a public health priority. FUNDING: Queensland Department of Health, National Health and Medical Research Council of Australia, National Drug and Alcohol Research Centre-University of New South Wales, Bill & Melinda Gates Foundation, University of Toronto, Technische Universität, Ontario Ministry of Health and Long Term Care, and the US National Institute of Alcohol Abuse and Alcoholism.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23993280     DOI: 10.1016/S0140-6736(13)61611-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  1648 in total

1.  Sedentary Behavior and Quality of Life in People with Psychotic Disorders from a Low Income Country: A Study from Uganda.

Authors:  Davy Vancampfort; Michel Probst; Simon Rosenbaum; Philip B Ward; Tine Van Damme; James Mugisha
Journal:  Community Ment Health J       Date:  2018-12-05

Review 2.  Psychometric properties of instruments for assessing depression among African youth: A systematic review.

Authors:  Massy Mutumba; Mark Tomlinson; Alexander C Tsai
Journal:  J Child Adolesc Ment Health       Date:  2014

3.  Evaluation of a Clinical Pharmacist-Led Multidisciplinary Antidepressant Telemonitoring Service in the Primary Care Setting.

Authors:  Shubha Bhat; Miranda E Kroehl; Katy E Trinkley; Zeta Chow; Lauren J Heath; Sarah J Billups; Danielle F Loeb
Journal:  Popul Health Manag       Date:  2017-12-06       Impact factor: 2.459

4.  PsychotherapyPlus: augmentation of cognitive behavioral therapy (CBT) with prefrontal transcranial direct current stimulation (tDCS) in major depressive disorder-study design and methodology of a multicenter double-blind randomized placebo-controlled trial.

Authors:  Malek Bajbouj; Sabine Aust; Jan Spies; Ana-Lucia Herrera-Melendez; Sarah V Mayer; Maike Peters; Christian Plewnia; Andreas J Fallgatter; Lukas Frase; Claus Normann; Nora Behler; Linda Wulf; Eva-Lotta Brakemeier; Frank Padberg
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-12-06       Impact factor: 5.270

5.  Sex differences in sub-anesthetic ketamine's antidepressant effects and abuse liability.

Authors:  Katherine N Wright; Mohamed Kabbaj
Journal:  Curr Opin Behav Sci       Date:  2018-03-02

Review 6.  Virtual Reality-Enhanced Extinction of Phobias and Post-Traumatic Stress.

Authors:  Jessica L Maples-Keller; Carly Yasinski; Nicole Manjin; Barbara Olasov Rothbaum
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

7.  Sleep Architecture and Mental Health Among Community-Dwelling Older Men.

Authors:  Stephen F Smagula; Charles F Reynolds; Sonia Ancoli-Israel; Elizabeth Barrett-Connor; Thuy-Tien Dam; Jan M Hughes-Austin; Misti Paudel; Susan Redline; Katie L Stone; Jane A Cauley
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2013-12-10       Impact factor: 4.077

8.  Access and rational use of psychotropic medications in low- and middle-income countries.

Authors:  P Padmanathan; D Rai
Journal:  Epidemiol Psychiatr Sci       Date:  2015-09-21       Impact factor: 6.892

9.  A distinct biomarker of continuous transcutaneous vagus nerve stimulation treatment in major depressive disorder.

Authors:  Yiheng Tu; Jiliang Fang; Jin Cao; Zengjian Wang; Joel Park; Kristen Jorgenson; Courtney Lang; Jun Liu; Guolei Zhang; Yanping Zhao; Bing Zhu; Peijing Rong; Jian Kong
Journal:  Brain Stimul       Date:  2018-01-31       Impact factor: 8.955

10.  Anti-Oxidative Effects of Melatonin Receptor Agonist and Omega-3 Polyunsaturated Fatty Acids in Neuronal SH-SY5Y Cells: Deciphering Synergic Effects on Anti-Depressant Mechanisms.

Authors:  Senthil Kumaran Satyanarayanan; Yin-Hwa Shih; Yu-Chuan Chien; Shih-Yi Huang; Piotr Gałecki; Siegfried Kasper; Jane Pei-Chen Chang; Kuan-Pin Su
Journal:  Mol Neurobiol       Date:  2018-02-03       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.